Pharmaceutical companies commonly used legal argument, as opposed to demonstrating proof of therapeutic efficacy, to overcome anti-evergreening objections
Live Mint | 27 April, 2018
India’s patent office is being too lenient on pharma patents
Global innovation and intellectual property rights lobbies often castigate India for its weak intellectual property framework that fails to recognise innovation and grant patents.
Economic Times Prime Reports | April 26, 2018
72% of drug patent grants in India for marginal improvements, says study
Majority of pharmaceutical drug patents granted by India might have skipped elaborate scrutiny, an analysis of patent grants by a team of researchers and patent lawyers reveals.
Business Today | April 25, 2018
IP undermines equity, progress
OVER the last few decades, people in the developing world have been rejecting the intellectual property (IP) regime as it has been increasingly imposed on them following the establishment of the World Trade Organisation (WTO), including its trade-related intellectual property rights (TRIPs) regime.
New Straits Times | February 26, 2018
Biologics, patents and drug prices
India’s rejection of secondary patents has kept blockbuster medicines affordable for many